Hedge Fund - RA Capital Management

Joint Filing Agreement by and among the Reporting Persons is incorporated herein by reference to Exhibit 1 to the Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission...

You can access the original SEC filing by clicking here.

Peter Kolchinsky's RA Capital Management has slightly raised its stake in Avexis Inc. (NASDAQ:AVXS), as per a new Form 13G with the Securities and Exchange Commission.

Peter Kolchinsky's RA Capital Management has slashed its position in Alcobra Ltd (NASDAQ:ADHD) to just under 1.31 million shares according to a new 13G filing with the SEC.

An amended 13G filing with the SEC revealed that Peter Kolchinsky's RA Capital Management has sold around 1.1 million shares of Aclaris Therapeutics Inc (NASDAQ:ACRS), decreasing its stake in the company...

Peter Kolchinsky's RA Capital Management reported via a recent 13G filing with the SEC that it has taken a new position in a company that has recently gone public, Protagonist Therapeutics Inc (NASDAQ...

RA Capital Management LLC is a crossover fund manager that invests in public and private healthcare and life science companies developing drugs, medical devices and diagnostics.

A recent 13G filing with the SEC revealed that Peter Kolchinsky's RA Capital Management has acquired more shares of Vitae Pharmaceuticals Inc (NASDAQ:VTAE), as it currently holds 2.12 million common...

Peter Kolchinsky's RA Capital Management has stepped up its interest in Ardelyx Inc. (NASDAQ:ARDX).